slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 20,581-20,610
Pages 885
Rows per page 30
Arc
20,581-20,610 of 26,550
03
Uses a comparison to the scale of the universe to frame the problem as an intractable search space.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · Problem1 hit
04
Uses a simple visual metaphor of a subset circle to illustrate the problem of low success rates in drug discovery.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · Problem1 hit
07
The slide uses a flywheel/cycle diagram to represent the iterative nature of their platform.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The central circular diagram represents a flywheel or iterative process.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
The slide uses a process flow diagram to explain the drug discovery pipeline from patient cohort to manufacturing.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
The slide uses a process flow diagram to illustrate the transformation of biological targets into optimized drug candidates.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a process-flow visual to contrast discovery vs. optimization.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide features the company logo and a stylized 'a' graphic.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide highlights a specific Nature Biomedical Engineering paper as validation of the company's core technology approach.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide uses a process flow diagram to show the transition from parental mAb to optimized mAb via AI.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide outlines a technical methodology for biological data generation.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide includes a small schematic icon representing the scatter plot and a callout box emphasizing the necessity of high-quality data for AI training.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table outlines the experimental design for antibody optimization models, specifically highlighting the differences in sampling strategies and mutational loads.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
The slide explains the methodology behind the dataset used for AI lead optimization, specifically focusing on the combinatorial space of amino acid mutations.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
Includes scatter plots showing correlation and a bar chart comparing model performance metrics against experimental replicates.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
02
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
03
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
04
Includes a list of abbreviations at the bottom.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
05
The slide uses a visual comparison framework to position TRuC-T cells as a superior technological evolution.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
The slide uses a 2x2 layout to present four distinct experimental results supporting the superiority of TRuC technology.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
07
The slide uses a comparative structure to frame gavo-cel as a superior therapeutic option compared to historical anti-mesothelin CAR-T approaches.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
08
The chart is a classic waterfall plot used in oncology clinical trials to demonstrate efficacy.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Waterfall plot showing individual patient responses; includes specific clinical trial metrics (ORR, PFS, OS).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
Waterfall plot shows individual patient responses; ORR, PFS, and OS metrics provided.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a vertical process flow to link four strategic modifications to two distinct patient groups (Ovarian/Mesothelioma and NSCLC/Cholangiocarcinoma).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
RP2D (Recommended Phase 2 Dose) is highlighted at DL 3.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table categorizes adverse events into Hematologic, On Target/On Tumor, On Target/Off Tumor, and Other, with a specific highlight on the RP2D (Recommended Phase 2 Dose) column.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
Waterfall plot is a standard clinical trial visualization for tumor response.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit